Establishment Labs raises 2026 full-year revenue guidance to $269 mln-$271 mln
Company expects strong growth in H2 2026 and throughout 2027
Result drivers
Minimally invasive platform - Co said accelerating adoption of its minimally invasive platform contributed to revenue growth and margin improvement
U.S. business growth - Continued growth of higher-margin U.S. business drove improvement in gross margin, per co
Operating leverage - Adjusted operating expenses increased 2.0% compared to revenue growth of 31.7%, demonstrating operating leverage as business scales
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Establishment Labs Holdings Inc is $98.00, about 7.4% above its August 5 closing price of $91.25
ESTA•
